drugset / Trial / NCT06326047

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047

Phase 2 Completed 299 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Timeline

Start
2024-03-18
Primary completion
2025-09-19
Completion
2025-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0519-0130 Unknown Subcutaneous
Comparator Tirzepatide Peptide Subcutaneous